Literature DB >> 31826733

Intravenously Transplanted Human Multilineage-Differentiating Stress-Enduring Cells Afford Brain Repair in a Mouse Lacunar Stroke Model.

Takatsugu Abe1, Daiki Aburakawa1, Kuniyasu Niizuma1,2,3, Naoya Iwabuchi1, Takumi Kajitani1, Shohei Wakao4, Yoshihiro Kushida4, Mari Dezawa4, Cesar V Borlongan5, Teiji Tominaga1.   

Abstract

Background and Purpose- Multilineage-differentiating stress-enduring cells are endogenous nontumorigenic reparative pluripotent-like stem cells found in bone marrow, peripheral blood, and connective tissues. Topically administered human multilineage-differentiating stress-enduring cells into rat/mouse stroke models differentiated into neural cells and promoted clinically relevant functional recovery. However, critical questions on the appropriate timing and dose, and safety of the less invasive intravenous administration of clinical-grade multilineage-differentiating stress-enduring cell-based product CL2020 remain unanswered. Methods- Using an immunodeficient mouse lacunar model, CL2020 was administered via the cervical vein in different doses (high dose=5×104 cells/body; medium dose=1×104 cells/body; low dose=5×103 cells/body) at subacute phase (≈9 days after onset) and chronic phase (≈30 days). Cylinder test, depletion of human cells by diphtheria toxin administration, immunohistochemistry, and human specific-genome detection were performed. Results- Tumorigenesis and adverse effects were not detected for up to 22 weeks. The high-dose group displayed significant functional recovery compared with the vehicle group in cylinder test in subacute-phase-treated and chronic-phase-treated animals after 6 weeks and 8 weeks post-injection, respectively. In the high-dose group of subacute-phase-treated animals, robust and stable recovery in cylinder test persisted up to 22 weeks compared with the vehicle group. In both groups, intraperitoneal injection of diphtheria toxin abrogated the functional recovery. Anti-human mitochondria revealed CL2020 distributed mainly in the peri-infarct area at 1, 10, and 22 weeks and expressed NeuN (neuronal nuclei)- and MAP-2 (microtubule-associated protein-2)-immunoreactivity. Conclusions- Intravenously administered CL2020 was safe, migrated to the peri-infarct area, and afforded functional recovery in experimental stroke.

Entities:  

Keywords:  bone marrow; infarction; mice; mitochondria; stem cells

Year:  2019        PMID: 31826733     DOI: 10.1161/STROKEAHA.119.026589

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  13 in total

1.  Intravenous injection of human multilineage-differentiating stress-enduring cells alleviates mouse severe acute pancreatitis without immunosuppressants.

Authors:  Masahiko Fukase; Naoaki Sakata; Yoshihiro Kushida; Shohei Wakao; Michiaki Unno; Mari Dezawa
Journal:  Surg Today       Date:  2021-10-23       Impact factor: 2.549

Review 2.  Neuroinflammation, Stem Cells, and Stroke.

Authors:  Stefan Anthony; Dorothy Cabantan; Molly Monsour; Cesario V Borlongan
Journal:  Stroke       Date:  2022-04-05       Impact factor: 10.170

3.  Intravenously delivered multilineage-differentiating stress enduring cells dampen excessive glutamate metabolism and microglial activation in experimental perinatal hypoxic ischemic encephalopathy.

Authors:  Toshihiko Suzuki; Yoshiaki Sato; Yoshihiro Kushida; Masahiro Tsuji; Shohei Wakao; Kazuto Ueda; Kenji Imai; Yukako Iitani; Shinobu Shimizu; Hideki Hida; Takashi Temma; Shigeyoshi Saito; Hidehiro Iida; Masaaki Mizuno; Yoshiyuki Takahashi; Mari Dezawa; Cesar V Borlongan; Masahiro Hayakawa
Journal:  J Cereb Blood Flow Metab       Date:  2020-11-22       Impact factor: 6.200

4.  Safety and tolerability of a multilineage-differentiating stress-enduring cell-based product in neonatal hypoxic-ischaemic encephalopathy with therapeutic hypothermia (SHIELD trial): a clinical trial protocol open-label, non-randomised, dose-escalation trial.

Authors:  Nao Matsuyama; Shinobu Shimizu; Kazuto Ueda; Toshihiko Suzuki; Sakiko Suzuki; Ryosuke Miura; Akemi Katayama; Masahiko Ando; Masaaki Mizuno; Akihiro Hirakawa; Masahiro Hayakawa; Yoshiaki Sato
Journal:  BMJ Open       Date:  2022-04-26       Impact factor: 3.006

5.  A Novel Type of Stem Cells Double-Positive for SSEA-3 and CD45 in Human Peripheral Blood.

Authors:  Tetsuya Sato; Shohei Wakao; Yoshihiro Kushida; Kazuki Tatsumi; Masaaki Kitada; Takatsugu Abe; Kuniyasu Niizuma; Teiji Tominaga; Shigeki Kushimoto; Mari Dezawa
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

Review 6.  Potential Mechanisms and Perspectives in Ischemic Stroke Treatment Using Stem Cell Therapies.

Authors:  Guoyang Zhou; Yongjie Wang; Shiqi Gao; Xiongjie Fu; Yang Cao; Yucong Peng; Jianfeng Zhuang; Junwen Hu; Anwen Shao; Lin Wang
Journal:  Front Cell Dev Biol       Date:  2021-04-01

Review 7.  Non-Tumorigenic Pluripotent Reparative Muse Cells Provide a New Therapeutic Approach for Neurologic Diseases.

Authors:  Toru Yamashita; Yoshihiro Kushida; Koji Abe; Mari Dezawa
Journal:  Cells       Date:  2021-04-20       Impact factor: 6.600

Review 8.  Cell-based treatment for perinatal hypoxic-ischemic encephalopathy.

Authors:  You Jeong Park; Cesario V Borlongan; Mari Dezawa
Journal:  Brain Circ       Date:  2021-03-30

Review 9.  A Museum of Stem Cells Points to Muse Cells as Robust Transplantable Cells for Stroke: Review.

Authors:  You Jeong Park; Jeffrey Farooq; Justin Cho; Blaise Cozene; Bella Gonzales-Portillo; Nadia Sadanandan; Madeline Saft; Jea Young Lee; Cesar V Borlongan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

10.  Therapeutic benefit of Muse cells in a mouse model of amyotrophic lateral sclerosis.

Authors:  Toru Yamashita; Yoshihiro Kushida; Shohei Wakao; Koh Tadokoro; Emi Nomura; Yoshio Omote; Mami Takemoto; Nozomi Hishikawa; Yasuyuki Ohta; Mari Dezawa; Koji Abe
Journal:  Sci Rep       Date:  2020-10-13       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.